ITM ISOTOPE TECHNOLOGIES MUNICH SE
ITM, a radiopharmaceutical biotech company, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. With patient benefit as the driving principle for all we do, ITM is advancing a broad pipeline, including two phase III studies, combining its high-quality radioisotopes with targeting molecules to develop precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.
For more information please visit: www.itm-radiopharma.com
ITM at a glance:
Field of Activity |
Precision Medicine, Precision Oncology, Targeted Radionuclide Therapy / PRRT |
Products/Services | 1.) Development of targeted radiopharmaceuticals for cancer treatment
Our lead candidate ITM-11 (n.c.a. 177Lu-edotreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is currently under investigation in two phase III clinical trials, COMPETE and COMPOSE. ITM-11 is a Targeted Radionuclide Therapeutic consisting of the high-quality radioisotope no-carrier-added lutetium-177 chelated to a somatostatin analogue to specifically target GEP-NETs. 2) Therapeutic & diagnostic radioisotopes 3) Equipment for Radiolabeling & Quality Control: iQS-Theranostics Synthesizer, iQS® Ga-68 Fluidic Labeling Module, Consumables (Reagent Sets, Cassettes), Quality Control Solution (radio-HPLC) 4) GMP Radiolabeling Service |
Unique Selling Point | ITM is an established company with a proven history as a radioisotope manufacturer and supplier and an emerging leader as a radiopharmaceutical company with a strong precision oncology drug development program including two phase III clinical trials. We are leveraging our expertise in drug development, GMP manufacturing, commercialization and global supply logistics for both diagnostic and therapeutic radioisotopes and radiopharmaceuticals to meet the needs of healthcare professionals and their patients across the globe. |
Membership in networks/associations |
BioM Biotech Cluster Development GmbH, BIO Deutschland e.V., ENETS European Neuroendocrine Tumor Society, INCA International Neuroendocrine Cancer Alliance, The Carcinoid Cancer Foundation, Inc. (Patient Organization) |
Date of Incorporation/ Number of Employees |
2004/350 |
Contact:
Address | Lichtenbergstr. 1 85748 Garching/Munich |
Telephone | +49 89 329 8986-600 |
info@itm-radiopharma.com | |
Web Address | www.itm-radiopharma.com |
Social Media | LinkedIn Twitter Facebook |
- ITM erhält Eigenkapitalinvestition über 33 Mio. EUR
- ITM erhält Eigenkapital über 25 Mio. EUR von Grand Pharma
- ITM und Grand Pharma vereinbaren Vermarktung zielgerichteter Radiopharmazeutika in Großchina
- ITM schließt Finanzierungsrunde über 25 Mio. EUR ab
- ITM aus Garching schließt 109 Mio USD Finanzierungsrunde ab
- Diagnose und Therapie zusammenbringen: Theranostics
- 20 Mio. EUR-Finanzierung für Theranostic-Firma ITM